Ross Barrett, Managing Partner of Cancer Focus Fund II, LP, invests exclusively in global cancer companies at the late preclinical. See contact routes.
Ross Barrett, Managing Partner of Cancer Focus Fund II, LP, invests exclusively in global cancer companies at the late preclinical through Phase I/II clinical trial stages, focusing on cell therapy, immunotherapy, targeted therapies, and radio-therapeutics. His distinctive thesis leverages a unique partnership with MD Anderson Cancer Center to fund first-in-class drugs ready for clinical evaluation at the world’s largest oncology trials program. Notable portfolio investments include $4.5 million in ImmunoGenesis for a solid tumor trial and $4.5 million in Eisbach for a Phase 1/2 study of EIS-12656, alongside support for KAHR’s anti-CD47 candidate in blood cancers.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Shreveport.
Investors like Ross Barrett · Full investor directory · Investor access · Company funding database